Comparative Pharmacology
Head-to-head clinical analysis: ATROPEN versus ATROPINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPEN versus ATROPINE SULFATE.
ATROPEN vs ATROPINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5). Blocks parasympathetic nerve impulses, leading to increased heart rate, bronchodilation, decreased secretions, and mydriasis.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine at parasympathetic postganglionic junctions. Increases heart rate, reduces exocrine secretions, relaxes smooth muscle in GI and GU tracts, and dilates pupils.
0.5 to 1 mg IV/IM/SC every 3 to 5 minutes as needed; maximum 3 mg total. For bradycardia: 0.5 mg IV every 3-5 minutes to a maximum of 3 mg. For organophosphate poisoning: 2 mg IV/IM initially, then 2 mg every 5-10 minutes until atropinization.
0.5 to 1 mg intravenously or intramuscularly every 3 to 5 minutes as needed, up to a total of 3 mg (3 doses) for bradycardia; 0.5 to 1 mg subcutaneously, intramuscularly, or intravenously every 4 to 6 hours for antisecretory effects; 1 to 2 mg intravenously every 5 minutes for organophosphate poisoning.
None Documented
None Documented
Terminal half-life ~2-3 hours in adults; prolonged in elderly and infants due to reduced clearance.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged in elderly and infants; clinically significant due to potential accumulation with repeated dosing.
Renal: ~50% unchanged; hepatic metabolism (hydrolysis) accounts for ~30-40%; fecal: <5%.
Renal excretion of unchanged drug and metabolites; ~50% excreted unchanged in urine; remainder as inactive metabolites (tropine, tropic acid); biliary/fecal excretion minor.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent